8月4日 - ** 百时美施贵宝（Bristol Myers Squibb） BMY.N 的股价正有望抹去自周日传出与阿斯利康（AstraZeneca） AZN.L 巨额交易谈判 (link) 消息以来所录得的微弱涨幅。
** 盘前股价下跌0.25%
** 多名分析师曾对这笔交易的益处表示怀疑
** “这一消息让我们有些困惑。如果说有哪家公司不需要财务工程，那肯定就是阿斯利康，”经纪公司杰富瑞（Jefferies）写道
** 周一，阿斯利康（AZN）股价遭遇猛烈抛售 (link)，导致其失去英国市值第二大公司的地位
** 能源巨头壳牌（Shell） SHEL.L 目前市值为1901.1亿英镑（合2556.3亿美元），已成为英国第二大上市公司
** 在有关这笔潜在交易的报道发布之前，BMY今年以来已上涨21%，而AZN则下跌了8.4%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.